Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
WEB3 days ago · Pleural mesothelioma is a type of cancer which develops in the tissue that lines the lungs or pleura. This is the first time Keytruda has been approved for the given indication in the United States.
FDA Approves Frontline Pembrolizumab/Chemotherapy in Advanced Mesothelioma
WEB4 days ago · The FDA has granted approval to the first-line treatment of pembrolizumab combined with chemotherapy in patients with unresectable advanced or metastatic malignant pleural mesothelioma. 1. Data from the randomized, open-label, phase 2/3 KEYNOTE-483 trial (NCT02784171) support this approval. 2 According to findings presented at the 2023 American ...
FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma
WEB5 days ago · A treatment regimen consisting of pembrolizumab (Keytruda) plus pemetrexed and platinum-based chemotherapy has earned FDA approval as a first-line therapy for patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM), according to a press release from the agency. 1. The regulatory agency approved pembrolizumab at a ...
New Drug to Treat Mesothelioma Hailed as a Major Breakthrough
WEBFeb 21, 2024 · ADI-PEG20 or pegargiminase is being hailed as the first drug of its kind to be incorporated successfully with chemotherapy in 20 years. Researchers say this new drug could bring hope to thousands of mesothelioma survivors and their families. The drug blocks the cancer’s food supply, ensuring the disease can’t spread.
Phase 3 Keytruda, Chemo Mesothelioma Trial Shows Promise
WEBJun 26, 2023 · Pharmaceutical company Merck says use of its immunotherapy drug Keytruda in conjunction with chemotherapy increases the survival rate for people with advanced pleural mesothelioma, according to the latest results of a phase 3 clinical trial.
Understanding the new therapeutic options for mesothelioma
WEBSep 6, 2021 · However, in October, 2020, the FDA-approved first-line treatment for mesothelioma was changed to ipilimumab plus nivolumab due to the compelling data from CheckMate 743. Although RAMES offers another option, it is unclear where it fits into this new treatment paradigm.
FDA Approves Drug Combination for Treating Mesothelioma
WEBOct 2, 2020 · Today, the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
FDA Grants Fast Track Designation to UV1 Vaccine Combo in …
WEBFeb 6, 2024 · The FDA has granted fast track designation to UV1, an investigational cancer vaccine, plus nivolumab (Opdivo) and ipilimumab (Yervoy) in the management of unresectable malignant pleural mesothelioma, according to a press release from Ultimovacs ASA, the developer of the vaccine. 1
Refreshing the mesothelioma catalogue: tailoring cellular therapy …
WEBJun 4, 2024 · There remains a large unmet need for improving the durability of first-line therapies. Many notable negative phase 3 trials in mesothelioma were inspired by promising phase 2 data, 9,10 leaving a field that is eager for …
Cancer Breakthrough: Innovative Mesothelioma Treatment …
WEBFeb 29, 2024 · The phase 3 clinical trial, led by Professor Peter Szlosarek at Queen Mary and sponsored by Polaris Pharmaceuticals, has unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer with limited therapeutic options.
Skip to content